Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors.

Jessica A WalshIris LinRuizhi ZhaoNatalie J ShiffLaura MorrisonBruno EmondLouise H YuSamuel SchwartzbeinPatrick LefebvreDominic PilonSoumya D ChakravartyPhilip Mease

Published in: Drugs - real world outcomes (2024)

This real-world study employing US commercial health-plan claims data to assess on-label treatment persistence in PsA demonstrated that, at 12 months, guselkumab was associated with a 3 times greater likelihood of persistence compared with SC TNFi.

Keyphrases

prostate cancer
healthcare
public health
rheumatoid arthritis
mental health
machine learning
big data
risk assessment
social media
data analysis